GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host C...

Date : 02/07/2019 @ 8:22PM
Source : GlobeNewswire Inc.
Stock : GW Pharmaceuticals Plc ADS (GWPH)
Quote : 168.83  -7.17 (-4.07%) @ 12:00AM

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host C...

GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
Historical Stock Chart

2 Months : From Jan 2019 to Mar 2019

Click Here for more GW PHARMACEUTICALS PLC Charts.

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February, 2019 its financial results for the quarter ending 31 December, 2018. This is a transition period as GW will be moving to a new fiscal year-ending 31 December following this report on Form 10K-T. GW will also host a conference call the same day at 4:30 p.m. EST. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company has submitted a regulatory application in Europe for the adjunctive treatment of seizures associated with LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has an ongoing clinical trial in tuberous sclerosis complex (TSC). GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:
   
 GW Pharmaceuticals plc 
 Stephen Schultz, VP Investor Relations (U.S.)917 280 2424 / 401 500 6570

Latest GWPH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.